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Abstract 
Constitutively active intracellular signaling drives and sustains cancer growth. 
The mTOR kinase integrates multiple inputs sensing nutrient, energy and 
growth factor levels to promote protein synthesis and anabolic metabolism, 
and is hyperactivated in a broad range of cancers. The bcr-abl kinase is a 
fusion protein generated by chromosomal translocation and gives rise to 
chronic myeloid leukemia and a small sub-set of leukemias. Using an in vitro 
transformed murine cell model, we performed shRNA knockdown of 25 genes 
previously shown to be essential for mTOR dependent oncogenic growth and 
survival. None of the genes were essential in the bcr-abl transformed line. 
Interrogation of this gene set in human cancer cell lines revealed that many of 
these genes were essential in cells dependent on mTOR signaling (defined by 
sensitivity to pharmacological mTOR inhibition). However, none of the genes 
were essential in bcr-abl transformed K562 cells that are insensitive to mTOR 
inhibition. Thus there is a clear divide between cells transformed via bcr-abl 
directed oncogenesis and other modes of transformation where mTOR, due to 
its central role in regulating cell growth and metabolism, is recruited as part of 
an oncogenic program. These validated hits represent a set of genes 
essential for executing critical functions downstream of mTOR and may be 
novel therapeutic targets for cancer.
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Introduction 
The mTOR signaling pathway is an important regulator of cellular 
homeostasis. By integrating inputs pertaining to nutrient, growth factor and 
energy levels, its output determines if a cell engages in anabolic processes 
(protein, nucleotide or lipid synthesis) under favourable conditions, or 
catabolic processes such as autophagy under adverse conditions [1]. mTOR 
is a serine/threonine kinase that forms two distinct multi-protein complexes: 
the raptor containing mTOR complex 1 (mTORC1) and rictor containing 
mTORC2. mTORC1 is regulated by nutrient availability and broadly controls 
translation, autophagy and metabolic processes. mTORC2 meanwhile, is 
growth factor regulated and via an important substrate, the Akt oncogene, 
controls cell survival. 
 Due to its critical role at the intersection between cell growth, 
metabolism and proliferation, dysregulated mTOR signaling is a frequent 
event in cancer [2]. Mutation of mTOR regulators such as TSC1/TSC2 or 
PTEN (that negatively regulate mTORC1 and mTORC2 respectively) are 
common oncogenic events that result in constitutive mTOR activity. Constant 
mTOR signaling provides support for cellular hyper-proliferation from the 
increased synthesis of required proteins and cellular building blocks.  
 We previously described an mTORC2 addicted cell model where 
murine mast cells are transformed by constitutive mTORC2 signaling 
following mutagenic knock-out of PTEN [3]. As a consequence these cells are 
exquisitely sensitive to mTOR inhibition compared to the parent cell line. A 
genome-wide shRNA screen identified genes that are conditionally essential 
for growth and survival only under an mTORC2-driven oncogenic program. 
These hits are thus candidate genes for effector proteins that are responsible 
for executing essential functions upon mTORC2 hyperactivation. 
 To confirm these hits, we re-screened the top 25 hits in an isogenic cell 
panel. Two independent PTEN deficient lines were derived from the parental 
cell line. In addition, the bcr-abl oncoprotein was used to transform the 
parental cell line via an alternative oncogenic pathway. The screen confirmed 
that these genes were also essential in the newly generated PTEN-
/mTORC2-addicted cell models. Strikingly none of the genes were essential in 
the bcr-abl transformed line. 
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 Here, we extended the study to a panel of human cancer cell lines. 
Two PTEN negative cell lines with high basal mTORC2 activity (OPM2, 
Jurkat) were selected, a PTEN positive leukemia cell line HL60, and a bcr-abl 
transformed CML cell line (K562). shRNA screening of the human 
counterparts of the hits previously validated in the murine cell line panel 
revealed that a substantial fraction were also essential for survival in the 
human cell line panel, with the exception of K562 where shRNA knockdown of 
these genes had little to no impact on growth and survival. Pharmacological 
inhibition of mTOR also had the least effect on K562 compared to the other 
cell lines, indicating that mTOR is not as critically required in bcr-abl mediated 
transformation. These results show that bcr-abl mediated transformation is 
distinct from oncogenic programs where mTOR is constitutively activated (as 
in the case of PTEN loss), or has been recruited to support cancer cell 
growth.
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Results 
In vitro transformation of mast cells  
We previously described an in vitro transformation system based on murine 
PB3c mast cells [4]. Parental 15V4 cells are dependent on exogenous 
interleukin-3 (IL3) for in vitro growth and survival. These cells can be 
transformed to acquire growth factor independence, a hallmark of cancer, by 
various routes [3-5]. Transformation to IL3 independence can be achieved by 
loss of Pten expression via mutagenesis (6.5 and 6.8 cells), and is 
phenocopied by stable shRNA knockdown of Pten (shP) (Fig 1A). The Pten- 
cell lines have hyperactive mTORC2 signaling as measured by 
phosphorylation of Akt at serine 473 (Fig 1B). Although mTORC1 activity is 
also increased in the Pten deficient cell lines (at threonine 389 of the 
mTORC1 target S6K), we previously showed that these cells are addicted to 
mTORC2 and not mTORC1 signaling for growth and survival [3]. An 
alternative route of in vitro transformation in this system is expression of the 
bcr-abl oncoprotein in 15V4 cells to generate IL3 independent b-abl cells (Fig 
1A) [6]. Unlike the Pten deficient cell lines, b-abl cells have similar basal levels 
of mTORC2 activity as the parental cells and a slight increase in mTORC1 
signaling (Fig 1B). 
 In these cells, IL3 signaling remains intact despite having lost their 
requirement for IL3. 6.8 cells are sensitive to rapamycin, as anticipated due to 
its addiction to mTORC2 signaling (Fig 1C). However rapamycin sensitivity is 
rescued by exogenous IL3, indicating that loss of mTORC2 signaling can be 
compensated by stimulation of IL3 signaling. Similar results were obtained 
with 6.5 and shP (data not shown). b-abl cells however, are sensitive to the 
bcr-abl inhibitor Glivec in the absence of IL3 and are rescued by exogenous 
IL3. 
In these titrations, b-abl cells are rapamycin insensitive while the 6.8 
cells are Glivec insensitive arguing that different downstream signaling 
pathways are activated to confer IL3 independence. Nonetheless both loss of 
mTOR or bcr-abl signaling can be compensated by IL3 signaling. 
 
Genes essential in mTORC2 addicted cells are not required in bcr-abl 
transformed cells 
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The ability to rescue cell lethality with exogenous IL3 allows identification of 
genes whose knockdown is conditionally lethal only in the absence of IL3. 
This was previously exploited to identify genes required for mTORC2 driven 
IL3 independent growth in 6.5, 6.8 and shP by a genome-wide shRNA screen 
[3]. To see if any of these genes are shared in common in bcr-abl mediated 
IL3 independence, we selected 25 of the highest scoring genes for screening 
in b-abl (the screen was repeated for 6.5, 6.8 and shP). For each gene, cells 
were infected with a lentivirus bearing the respective targeting shRNA 
(typically 5 different shRNA contructs per gene) in the presence or absence of 
IL3, and growth measured 5 days post-infection. Thus for each shRNA 
construct, a ratio of inhibition (RI) could be calculated by dividing 
proliferation+IL3/proliferation-IL3 (normalized to infection by a nontargeting 
shControl virus). The mean RI of the two highest scoring shRNAs was taken 
for each gene (Table S1). 
 The mean RI of the 25 genes are plotted for all 4 cell lines in Fig 1D. 
The RI’s for the mTORC2 addicted (6.5, 6.8 and shP) and b-abl cells form two 
distinct non-overlapping classes. Strikingly, shRNA knockdown of none of the 
genes has an effect on b-abl viability suggesting that they are not involved in 
bcr-abl driven IL3 independence. We set an arbitrary cut-off and analyzed 
genes having an RI greater than 20% (Fig 1E). Expectedly, as these are 
mTORC2 addicted cells, mTOR is a hit in all 3 cell lines while the mTORC2 
specific component Rictor is also a hit in 2/3 cell lines. Several genes 
(mRPL27, Cox7A2l, Mff, Dmgdh) have mitochondrial functions, and as 
previously described, mitochondrial activity is critical for the mTORC2 
addicted cells[3]. However, the remaining genes form a seemingly 
heterogeneous group that may nevertheless share a common role as being 
downstream effectors of mTORC2 signaling. 
 
A substantial fraction of genes essential in murine mTORC2 addicted cells are 
also essential in human cancer cell lines 
To extend these findings from an in vitro transformed murine cell model to 
human cancer, we selected known PTEN negative cell lines OPM2 (multiple 
myeloma) and Jurkat (T-cell leukemia) as these cells have high constitutive 
mTORC2 activity. K562 (chronic myelogenous leukemia) expresses the bcr-
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abl oncoprotein and was chosen to see whether it would represent an outlier 
with respect to the other cell lines, similar to the b-abl cell line in the murine 
cell panel. HL60 (acute myeloid leukemia-M2) is PTEN positive and does not 
express bcr-abl, it is however insulin dependent for in vitro growth indicating a 
requirement for mTORC2 signaling [7]. Basal mTOR activity of these cell lines 
under nutrient-replete conditions (similar conditions as in shRNA screens) 
was determined by immunoblotting. PTEN negative OPM2 and Jurkat cells as 
expected had high mTORC2 activity, and slight elevation of mTORC1 
signaling (Fig 2A).  
 Lentiviral particles for the human counterparts of the 25 essential 
genes in the mTORC2 addicted murine cells were obtained and used to 
screen the human cell panel. Unlike the previous screen, there was no 
possibility of growth factor stimulation corresponding to IL3 to rescue the 
knockdown of an essential gene. Therefore we needed to measure the 
infectious titer of each virus in order to discern if an effect on proliferation is 
biologically relevant due to the knockdown of its target gene, or a technical 
artefact due to low viral titer. To this end, we infected mouse bcr-abl cells with 
the human targeting lentiviruses and selected for puromycin resistance. The 
level of proliferation (as denoted by acquired puromycin resistance) was taken 
as a measure of the viral titer and was used to normalize infectivity of all the 
viruses (Table S2). shRNA's targeting the essential ribosomal genes RPL32 
and RPS17 served as positive controls for cell death. Knockdown of both 
ribosomal genes were lethal, with RPS17 being more effective and was used 
to set a baseline for cell death (Table S2). 
 Reduction in cell proliferation after shRNA knockdown of the 25 genes 
in the human cell panel is shown in Fig 2B. The ratio of inhibition for each 
lentivirus was calculated from (growth in infected human cells)/(growth in 
infected b-abl cells) and normalized to the RI of RPS17. The RI for each gene 
was the mean of the two best lentiviruses. shRNA knockdown of a substantial 
fraction of the genes inhibited proliferation in all the cell lines with the 
exception of bcr-abl transformed K562. This parallels the results seen in the 
mouse panel where only the b-abl line was unaffected by shRNA knockdown 
of the corresponding murine genes. Accordingly, we set a threshold for 
effectiveness above the K562 cluster (corresponding to a reduction in 
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proliferation greater than 19%, red dashed line). In the non bcr-abl 
transformed lines, knockdown reduces cell proliferation in around half of the 
genes targeted (Fig 2C). Rictor knockdown was positive in all 3 cell lines and 
mTOR in 2 out of 3 lines (Fig 2D). Genes encoding for mitochondrial function 
(MRPL27, Cox7A2l, Mff, Dmgdh) were once again essential. 
 Thus the list of 25 essential genes obtained from the isogenic 
mTORC2-addicted murine screen translates very well to a heterogeneous 
panel of human cancer cell lines. Some of these hits, in particular those from 
the PTEN negative OPM2 and Jurkat lines, may be due to increased 
mTORC2 signaling required for oncogenic growth. However, a large number 
of these hits are also shared in common with HL60 where mTOR signaling is 
not particularly elevated. None of these hits have a strong impact on growth in 
K562 suggesting a distinct difference between bcr-abl mediated 
transformation and other modes of oncogenic transformation with regard to 
mTOR involvement. 
 
Different requirement for mTOR signaling in bcr-abl and non bcr-abl 
transformed cells 
To investigate dependency on mTOR signaling, cells were titrated with 
rapamycin and growth measured after 3 days. OPM2 was highly sensitive to 
rapamycin while K562 was least affected (Fig 3A). HL60 and Jurkat cells had 
reduced proliferation that may be due to the general cytostatic effect of 
rapamycin on cell proliferation. However, reduced proliferation in OPM2 after 
rapamycin treatment appears greater than expected from growth arrest alone. 
Annexin V staining showed rapamycin induced apoptosis in OPM2 cells while 
having no effect on K562 (Fig 3B). Rapamycin only partially inhibits mTORC1 
and is usually ineffective on mTORC2. We therefore used Torin1, an active 
site inhibitor of both mTORC1 and mTORC2 [8]. Torin1 had a strong negative 
effect on cell proliferation in HL60 and OPM2 and also decreased growth of 
Jurkat cells (Fig 3A). Inhibition of both TOR complexes however, had little 
effect on proliferation in K562.  
 To further dissect the role of mTOR signaling, we performed shRNA 
knockdown of Rictor and Raptor on cell lines with the greatest divergence in 
response to mTOR inhibition, namely OPM2 and K562. shRNA knockdown of 
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Raptor (mTORC1) or Rictor (mTORC2) was deleterious to OPM2 while 
having little effect on K562 (Fig 3C, 3D). Thus both mTORC1 and mTORC2 
are essential for OPM2 growth and viability. In contrast mTOR signaling does 
not appear to be critical in K562, at least over the time-scale of the assay. 
 
PHD3 is essential for growth and survival in mTOR dependent OPM2 
We wished to identify potential cancer therapeutic targets from the list of hits 
in Table S2. Of the essential genes in non bcr-abl transformed lines, only 
mTOR, Rictor, ATP1b3 and PHD3 can be pharmacologically inhibited. Rictor 
and mTOR signaling are already recognised as bona fide drug targets in 
oncology while inhibitors of ATP1b3 are non-specific and broadly target many 
Na+/K+ ATPase transporters. We focused on PHD3 (Prolyl hydroxylase 3, 
EGLN3) which is druggable and has been implicated in cancer [9]. 
 A growth assay for cells treated with the general prolyl hydroxylase 
inhibitor DMOG (Fig 4A) showed that OPM2 was the most sensitive and K562 
the least sensitive cell line. Thus response to DMOG within the cell panel 
mirrors sensitivity to the mTOR inhibitors rapamycin and Torin1 (Fig 3A). 
OPM2 acutely treated with DMOG showed reduced phosphorylation of S6K 
but not 4EBP (Fig 4B). DMOG appears to selectively inhibit phosphorylation 
of mTORC1 substrates in a similar fashion as rapamycin [10]. 
 DMOG inhibits all three cellular prolyl hydroxylases. To determine if the 
effect on growth was specific to PHD3 inhibition, OPM2 and K562 were 
infected with lentiviruses bearing shRNAs targeting PHD3. The degree of 
PHD3 knockdown correlated with growth suppression in OPM2 (Fig 4C, 4D). 
The great number of dying cells in OPM2 infected with shPHD3-49 reduced 
the amount of protein extracted for immunoblotting (Fig 4D, GAPDH loading 
control). In contrast, PHD3 knockdown had no effect on growth in K562.
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Discussion 
 Upregulation of mTOR signaling is a common event in cancer. 
mTORC1 promotes anabolic processes such as protein translation, lipid and 
nucleotide biosynthesis and suppresses catabolic processes like autophagy 
[11].  
Under normal conditions this maintains the balance between anabolism and 
catabolism for homeostasis. However hyperactivation in cancer supports 
unrestricted growth due to elevated anabolic synthesis of cellular 
components. mTORC2 phosphorylates several members of the AGC kinase 
family. Among its downstream effects are regulation of cytoskeletal 
remodeling and migration, and via Akt (an important oncogene), it also 
promotes cell proliferation and survival. The full spectrum of mTOR's role in 
the cell still remains to be characterised and there are presumably many more 
activities perturbed by mTOR dysregulation that are beneficial for cancer 
proliferation. Thus mTOR hyperactivation, even in cases where the driver 
mutation does not directly activate mTOR, is often recruited by oncogenic 
growth programs to support unrestricted proliferation. 
 The bcr-abl oncoprotein results from fusion of the abelson kinase gene, 
(ABL1) on chromosome 9, with the breakpoint cluster gene (BCR) on 
chromosome 22. The Abl kinase domain of bcr-abl is constitutively active due 
to loss of an autoinhibitory domain. Bcr-abl signaling causes chronic 
myelogenous leukemia and some cases of acute lymphoblastic leukemia or 
acute myelogenous leukemia [12]. Bcr-abl activates multiple downstream 
pathways (RAS/MAPK/ERK, JAK/STAT). The narrow range of histotypes 
generated by bcr-abl fusion however, indicates that the oncogenic program 
set in motion by bcr-abl signaling is restricted to cells from the hematopoietic 
lineage.  
 Our results show that genes essential for survival in an mTORC2 
driven murine cancer model are not required in an isogenic bcr-abl driven 
cancer model (Fig 2A). This indicates that different signaling networks are 
activated downstream of either oncogenic driver (Pten loss vs. bcr-abl 
expression), and that these networks do not appear to share common effector 
proteins to execute the various essential functions. 
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 This observation with the mouse model could be extended to human 
cancer cell lines. A substantial fraction of human counterparts of the genes 
previously validated in the murine model were also essential in a human cell 
line panel with the exception of bcr-abl transformed K562. In contrast to the 
other cell lines (OPM2, Jurkat, HL60), K562 was insensitive to 
pharmacological mTOR inhibition and shRNA knockdown of mTOR 
complexes. We could thus confirm a clear divide between the suite of 
essential genes in an mTOR dependent vs. bcr-abl transformed phenotype.  
The cell lines were initially selected without consideration for mTOR 
dependency. However the central importance of mTOR in coordinating cell 
growth and metabolism with nutrient and growth factor availability, results in 
the recruitment of mTOR hyperactivation regardless of the original oncogenic 
lesion. Thus there may be a general dependency for mTOR signaling to be 
recruited in diverse oncogenic programs (with bcr-abl oncogenic signaling 
being an exception). 
 The validated hits are potential cancer therapeutic targets. Among 
druggable targets, we focused on PHD3. While generally regarded as a tumor 
suppressor, PHD3 overexpression is a marker for poor prognosis in clear-cell 
renal cell carcinoma (ccRCC) [13], one of the few cancers to respond to 
rapamycin treatment [14] and supports translation and glycolysis in ccRCC 
[15]. Depletion of PHD3 activity by pharmacological inhibition or shRNA 
knockdown led to growth reduction and decreased mTORC1 signaling in 
OPM2 (Fig 4B, 4C). mTORC1 activation was previously shown to be sensitive 
to PHD inhibition [16]. Thus PHD3 is essential for cell viability in a 
transformed cell line where mTOR signaling is involved in driving cell growth 
and proliferation. 
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Materials and Methods 
Cell culture 
All cells were grown in Iscove’s medium supplemented with 10% FCS, 2mM 
L-glutamine, 100U/ml penicillin, 100µg/ml streptomycin and 50µM b-
mercaptoethanol at 37°, 5% CO2. Derivation of 15V4, 6.5, 6.8 and shP cells 
has been previously described [3]. b-abl cells were obtained by expressing a 
bcr-abl construct in 15V4 and selecting for IL3 independence [6]. Murine mast 
cell medium was supplemented with mouse IL3 from conditioned medium as 
previously described [3]. 
 
Cell proliferation assays 
Cells were plated in 96-well microtitre plates at a density of 3000 cells/150µl 
medium and growth measured after 3 days by addition of 0.1vol resazurin 
(final concentration 50µM). Fluorescence was read at 535/595nm (Ex/Em) 
with a plate reader. 
 
Immunoblotting 
Cells were lysed in RIPA buffer (containing protease and phosphatase 
inhibitors) and total protein (20µg) loaded on SDS-PAGE gels. Proteins were 
blotted onto nitrocellulose membranes and probed with commercially 
available antibodies against pS6K T389 (#9205), pAkt S473 (#9271), PTEN 
(#9559), total S6K (#9202), total Akt (#9272), Raptor (#2280), Rictor (#2114) 
from Cell Signaling, PHD3 (Thermo Fisher PA1-16526) and GAPDH (Abcam 
ab9385). Signals were detected with HRP-conjugated secondary antibodies 
and visualized with ECL detection reagent (GE Healthcare). 
 
shRNA knockdown screens 
MISSION TRC shRNA lentiviral library containing 80’000 lentiviral clones 
targeting 15’000 genes was purchased from Sigma-Aldrich. Cells (3,000 per 
well) were infected with individual lentiviruses (at a m.o.i. of ~1) in separate 
wells using a robotic platform. After 24h infection, cells were plated either 
with/without IL3 and puromycin (0.8 µg/ml) added to kill non-infected cells. On 
day 5, relative growth (compared to infection with shControl virus) was 
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quantified by measuring cell proliferation with resazurin, and 
Growth+IL3/Growth-IL3 was used to calculate a ratio of inhibition (RI). The RI 
was calculated using the mean of the two best performing shRNA constructs 
per gene (there are usually 5 shRNAs per gene).  
 Similar steps were carried out for the human shRNA screen, except for 
omission of a parallel +IL3 screen. Actual lentiviral infectivity was determined 
by measuring acquired puromycin resistance in murine bcr-abl cells 
(assuming that shRNAs targeting the human gene would be ineffective on 
their murine homologs). This allowed normalization of viral titers across all the 
lentiviruses used. The ratio of inhibition for a particular lentivus was calculated 
by dividing (proliferation in infected human cells)/(proliferation in murine b-abl 
cells). Lentiviruses targeting the essential ribosomal genes RPL32 and 
RPS17 were used as positive controls for cell death. The ratio of inhibition for 
RPS17 was set at 100% and all other ratios expressed as a percentage of 
this. 
 
shRNA lentiviruses 
Lentiviral article were ordered from Sigma-Aldrich. Human Raptor 
(TRCN0000039772), human Rictor (TRCN0000074290, TRCN0000289691), 
human PHD3 (TRCN0000001049, TRCN0000001050). Cells were infected 
overnight 
 
FACS analysis 
Cells were stained with Annexin V (Invitrogen) and counter stained with 
propidium iodide (5µg/ml) as a vital stain. Apoptotic cells detected by FACS 
analysis in the FL-1 channel and living cells were simultaneously detected in a 
separate channel. 
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Figure Legends 
Fig 1 (A) Flow scheme of the in vitro transformation from IL3-dependent 
parental cells to IL3-independence. (B) Immunoblot showing constitutively 
active mTORC2 in PTEN- but not in b-abl transformed cell-lines. (C) Growth 
assay for cells treated for 3 days with rapamycin or Glivec. Growth was 
normalized to vehicle treated controls. Each data point was performed in 
triplicate and error bars are SD of the mean. (D) Inhibition of proliferation in 
the murine mast cell panel after shRNA knockdown of selected genes. The 
ratio of inhibition (RI) was calculated using the mean of the two best 
performing shRNAs and was a ratio of the growth-IL3/growth+IL3. (C) Venn 
diagram of genes having an RI>20%. 
 
Fig 2 (A) Immunoblot for read-outs of mTOR activity in the human cancer cell 
line panel. (B) Inhibition of cell proliferation in the human cancer cell panel 
after shRNA knockdown of the human counterparts of the selected hit-list 
genes. Essential ribosomal genes RPL32 and RPS17 were positive controls 
for knockdown lethality. The ratio of inhibition (RI) was calculated using the 
mean of the two best performing shRNA constructs per gene normalized to 
RPS17 knockdown. (C) Venn diagram of genes having an RI>19%. (D) List of 
genes from (C). 
 
Fig 3 (A) Cell proliferation curves of the human cancer cell lines after 
treatment for 3 days with mTOR inhibitors. (B) FACS analysis of K562 and 
OPM2 cells stained for the apoptotic marker AnnexinV after treatment with 
rapamycin for 20 hours. (C) Proliferation of K562 and OPM2 cells 3 days after 
shRNA knockdown of Raptor and Rictor. (D) Immunoblot verifying Raptor and 
Rictor shRNA knockdown. 
 
Fig 4 (A) Cell proliferation curves of the human cancer cell lines after 
treatment for 3 days with DMOG. (B) Immunoblot for mTOR activity read-outs 
in OPM2 after 1 hour drug treatment. (C) Proliferation of K562 and OPM2 
cells after PHD3 shRNA knockdown. (D) Immunoblot verifying shRNA 
knockdown of PHD3.  
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Figure 1 
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Figure 3 
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Figure 4 Fig 5
A) B)
D)
0 
20 
40 
60 
80 
100 
120 
0.0001 0.001 0.01 0.1 1 10 
%
 G
ro
w
th
mM DMOG
OPM2 Jurkat HL60 K562
PHD3
GAPDH 
sh
CT
RL
sh
PH
D
3-
49
sh
PH
D
3-
50
sh
CT
RL
sh
PH
D
3-
49
sh
PH
D
3-
50
K562 OPM2
pS473 Akt
Akt
pT37/46 4EBP1
4EBP1
pS65 4EBP1
4EBP1
pT389 S6K
S6K
D
M
S
O
D
M
O
G
R
ap
a
To
rin
1
C)
0 
20 
40 
60 
80 
100 
120 
Uninf  shCTRL  PHD3-49 PHD3-50 
%
 G
ro
w
th
 
OPM2 K562 
.CC-BY-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/737817doi: bioRxiv preprint first posted online Aug. 16, 2019; 
	   22	  
Supplementary Data 
Table S1 
Ratio of inhibition for the 25 top-scoring genes in 3 mTORC2-addicted lines 
(6.5, 6.8, shP), and in b-abl cells. RI values for each gene using the mean of 
two best scoring oligos for growth-IL3/growth+IL3 were calculated as described 
[3]. An RI value >5 corresponds to inhibition of proliferation by >80%. 
 
Table S2 
Ratio of inhibition for the human homologs of the 25 genes from Table S1 
tested on a panel of human cancer cell lines. Essential ribosomal genes 
RPL32 and RPS17 were included as positive controls for cell death. RI for 
each shRNA was normalized to RPS17.  
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Table S1 
 
Gene symbol NM id Gene name Mean of Two 6.5 Mean of Two 6.8 Mean of Two shP Mean of Two b-abl
Abca3 NM_013855 ATP-binding cassette 22.5 33.3 30.4 3.6
Aqp1 NM_007472 aquaporin 1 10.3 30.7 6.4 0.8
Aqp7 NM_007473 aquaporin 7 12.7 64.7 23.1 1.2
Arsb NM_009712 arylsulfatase B 16.3 19.4 26.8 0.9
Asb15 NM_080847 ankyrin repeat and SOCS box-containing protein 15 11.0 65.6 8.5 0.7
Atp1b3 NM_007502 ATPase 20.1 33.3 15.2 3.7
Cbx2 NM_007623 chromobox homolog 2 (Drosophila Pc class) 10.2 8.0 7.2 1.9
Cox7a2l NM_009187 cytochrome c oxidase subunit VIIa polypeptide 2-like 23.2 12.9 26.9 2.8
Dmgdh NM_028772 dimethylglycine dehydrogenase precursor 13.9 23.5 17.3 1.8
Fhl3 NM_010213 four and a half LIM domains 3 23.2 63.6 34.6 3.6
Il1f5 NM_019451 interleukin 1 family 23.8 86.7 16.1 1.5
Kctd11 NM_153143 potassium channel tetramerisation domain containing 11 7.4 29.4 5.4 1.3
Mﬀ NM_029409 Mitochondrial fission factor 10.6 32.1 6.4 1.3
Mmd2 NM_175217 monocyte to macrophage diﬀerentiation-associated 2 9.0 16.6 13.2 1.8
Mrpl27 NM_053161 mitochondrial ribosomal protein L27 19.2 24.8 28.3 1.0
mTOR NM_020009 mammalian Target Of Rapamycin 24.5 69.7 64.9 0.8
Phykpl NM_028398 5-phosphohydroxy-L-lysine phospho-lyase 12.9 13.3 9.6 1.3
Prdm4 NM_181650 PR domain containing 4 34.2 89.0 55.7 3.9
Phd3 NM_028133 Prolyl hydroxylase 3 12.8 14.9 9.2 1.1
Rab32 NM_026405 RAB32 16.3 48.0 13.1 1.1
Rab33a NM_011228 RAB33A 7.9 46.2 26.8 1.2
Rictor NM_030168 Rictor 29.7 76.4 10.3 0.7
S100a11 NM_016740 S100 calcium binding protein A11 9.8 11.3 24.9 1.4
Sfn NM_018754 stratifin 22.7 30.4 23.6 1.3
Sh3bp2 NM_011893 SH3-domain binding protein 2 8.8 40.8 5.8 1.2
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Table S2 
 
 
 
Symbol Refseq ID Gene Description B-abl % 
proliferation
K562 mean 
norm. ratio
HL60 
mean 
norm. ratio
OPM2 
mean 
norm. ratio
Jurkat 
mean 
norm. ratio
RPL32 NM_000994 ribosomal protein L32 96.92 73.14 80.05 86.56 82.62
RPS17 NM_001021 ribosomal protein S17 117.74 100.00 100.00 100.00 100.00
ABCA3 NM_001089 ATP-binding cassette, sub-family A (ABC1), member 79.73 -2.29 23.11 76.93 0.53
AQP1 NM_000385 aquaporin 1 (Colton blood group) 49.57 2.43 17.35 13.32 16.53
AQP7 NM_001170 aquaporin 7 126.36 15.80 29.93 6.37 48.00
ARSB NM_000046 arylsulfatase B 134.68 12.49 7.79 22.34 42.06
ASB15 NM_080928 ankyrin repeat and SOCS box-containing 15 134.18 15.09 11.96 96.86 47.30
ATP1B3 NM_001679 ATPase, Na+/K+ transporting, beta 3 polypeptide 94.65 15.80 41.98 32.46 74.79
CBX2 NM_032647 chromobox homolog 2 (Pc class homolog, Drosophila) 110.87 9.30 40.35 34.55 5.94
COX7A2L NM_004718 cytochrome c oxidase subunit VIIa polypeptide 2 like 93.59 0.94 18.73 46.26 5.56
DMGDH NM_013391 dimethylglycine dehydrogenase 75.62 -0.17 23.29 41.81 9.23
FHL3 NM_004468 four and a half LIM domains 3 129.59 4.59 21.09 19.10 15.97
IL1F5 NM_012275 interleukin 1 family, member 5 (delta) 70.88 18.90 18.94 31.50 35.98
KCTD11 NM_001002914 potassium channel tetramerisation domain containing 11 93.83 0.75 11.24 12.08 10.55
MFF NM_020194 mitochondrial fission factor 35.42 -6.51 27.85 58.36 -9.87
MMD2 NM_198403 monocyte to macrophage diﬀerentiation-associated 88.91 6.05 7.85 9.07 -5.37
MRPL27 NM_016504 mitochondrial ribosomal protein L27 78.97 1.55 53.80 16.33 -2.02
mTOR NM_004958 mammalian Target Of Rapamycin 123.72 13.09 19.16 87.79 25.83
Phykpl NM_032921 5-phosphohydroxy-L-lysine phospho-lyase 134.94 14.18 37.48 11.66 27.55
PRDM4 NM_012406 PR domain containing 4 123.99 13.24 54.91 31.08 38.29
PHD3 NM_022073 prolyl hydroxylase 3 52.74 16.28 35.68 54.89 44.18
RAB32 NM_006834 RAB32, member RAS oncogene family 122.18 4.36 124.37 31.00 33.22
RAB33A NM_004794 RAB33A, member RAS oncogene family 31.38 12.86 22.74 36.19 18.44
RICTOR NM_152756 rapamycin-insensitive companion of mTOR 108.51 10.56 26.84 48.04 56.91
S100A11 NM_005620 S100 calcium binding protein A11 79.93 11.85 1.88 56.36 51.44
SFN NM_006142 stratifin 135.48 2.61 6.73 31.56 7.21
SH3BP2 NM_003023 SH3-domain binding protein 2 126.35 8.30 19.83 31.07 24.38
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